A Phase 2 interventional study of Paclitaxel and Sapanisertib in Endometrial Neoplasms, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 78 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-24.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing paclitaxel in Endometrial Neoplasms — 8 open to participants now, 14 under way, 3 of them phase 3. Paclitaxel · Endometrial Neoplasms.
Among the 39 studies testing paclitaxel in Endometrial Neoplasms, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2016, is one of 26 in phase 2, and was the 22nd registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →8 of the 39 studies testing paclitaxel in Endometrial Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in China
Ages 18+ · Women only
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–75 · Women only
Faeth Therapeutics · Sites in United States
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 42 across the 34 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 1 study filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing paclitaxel in Endometrial Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06317311GlaxoSmithKlineA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | 2026-12-14 |
| NCT05691010Memorial Sloan Kettering Cancer CenterA Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | 2027-01-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 39 studies testing paclitaxel in Endometrial Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.
The drugs being evaluated in this study are sapanisertib and MLN1117. Sapanisertib is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. This study will evaluate the efficacy and safety of each drug or drug combination.
The study will enroll approximately 241 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of 4 treatment groups:
Participants will receive either paclitaxel intravenous (IV) weekly, Paclitaxel IV along with sapanisertib orally, sapanisertib orally, or sapanisertib and MLN1117 orally.
This is a multicenter, multinational trial. Participants will make multiple visits to the clinic, with an end of treatment visit (EOT) which will occur 30 to 40 days after receiving their last dose of study drug or before the start of any subsequent anticancer therapy. After EOT, participants will be followed for PFS and overall survival (OS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants who:
Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:
Exclusion Criteria:
History of any of the following within the last 6 months before administration of the first dose of study drug:
Significant active cardiovascular or pulmonary disease before administration of the first dose of study drug, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paclitaxel 80 milligrams per square meter (mg/m\^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 13 weeks).
Drug: Paclitaxel
Paclitaxel 80 mg/m\^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 20 weeks).
Drug: Paclitaxel · Drug: Sapanisertib
Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 6 weeks).
Drug: Sapanisertib
Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 8 weeks).
Drug: Sapanisertib · Drug: MLN1117
Paclitaxel intravenous solution.
Sapanisertib capsules.
Also known as: MLN0128, INK128, TAK-228
MLN1117 capsules.
Also known as: TAK-117, INK1117
Progression Free Survival (PFS)
PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Up to approximately 30 months
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From the first dose of study drug through 30 days after the last dose of study drug (Up to approximately 54 months)
Overall Survival (OS)
OS is defined as the time in months from the date of randomization to the date of death.
Time frame: Up to approximately 54 months
Time to Tumor Progression (TTP)
TTP is defined as the time in months from the date of randomization to the date of first documentation of progression. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Up to 30 months
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieved a best response of a complete response (CR) or partial response (PR). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
Time frame: Up to 30 months
Clinical Benefit Rate (CBR)
CBR is defined as the percentage of participants with CR or PR or SD (SD of any duration). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Up to 30 months
Clinical Benefit Rate (CBR) at Week 16 (CBR-16)
CBR-16 is defined as the percentage of participants who achieved CR or PR of any duration or have SD with a duration of at least 16 weeks. Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Week 16
Participants took part in the study at 60 investigative sites in Australia, Belgium, Germany, Italy, Netherlands, Norway, Spain, United Kingdom, Canada and the United States from 01 April 2016 to 30 October 2020.
| Milestone | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| Started | 90 | 90 | 41 | 20 |
| Started | 90 | 90 | 41 | 20 |
| Completed | 18 | 20 | 3 | 2 |
| Completed | 18 | 20 | 3 | 2 |
| Not completed | 72 | 70 | 38 | 18 |
| Withdrew: Death | 58 | 59 | 30 | 16 |
| Withdrew: Lost to follow-up | 4 | 3 | 0 | 1 |
| Withdrew: Site terminated by sponsor | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 6 | 8 | 1 |
| Withdrew: Reason not specified | 2 | 1 | 0 | 0 |
PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| months | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 3.7 (2.3 to 4.5) | 5.6 (3.8 to 6.2) | 2.1 (1.9 to 3.5) | 2.0 (1.5 to 3.3) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 87 | 86 | 41 | 20 |
OS is defined as the time in months from the date of randomization to the date of death.
| months | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| Overall Survival (OS) | 12.7 (9.8 to 19.6) | 13.8 (9.9 to 19.1) | 12.5 (9.0 to 15.7) | 11.1 (2.7 to 17.5) |
TTP is defined as the time in months from the date of randomization to the date of first documentation of progression. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| months | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| Time to Tumor Progression (TTP) | 3.7 (2.5 to 5.4) | 5.7 (3.8 to 7.2) | 2.3 (1.9 to 4.2) | 2.2 (1.8 to 3.7) |
ORR is defined as the percentage of participants who achieved a best response of a complete response (CR) or partial response (PR). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
| percentage of participants | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| Overall Response Rate (ORR) | 18.4 | 24.4 | 4.9 | 0 |
CBR is defined as the percentage of participants with CR or PR or SD (SD of any duration). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| percentage of participants | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| Clinical Benefit Rate (CBR) | 57.5 | 80.2 | 34.1 | 35.0 |
CBR-16 is defined as the percentage of participants who achieved CR or PR of any duration or have SD with a duration of at least 16 weeks. Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| percentage of participants | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| Clinical Benefit Rate (CBR) at Week 16 (CBR-16) | 36.8 | 51.2 | 17.1 | 5.0 |
Collected over Up to the end of study (approximately up to 54 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paclitaxel 80 mg/m^2 | 58/90 (64.4%) | 23/87 (26.4%) | 85/87 (97.7%) |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | 59/90 (65.6%) | 47/86 (54.7%) | 86/86 (100%) |
| Sapanisertib 30 mg | 30/41 (73.2%) | 14/41 (34.1%) | 41/41 (100%) |
| Sapanisertib 4 mg + MLN1117 200 mg | 16/20 (80%) | 7/20 (35%) | 20/20 (100%) |
| Event | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/87 | 2/86 | 2/41 | 2/20 |
| VomitingGastrointestinal disorders | 0/87 | 2/86 | 2/41 | 2/20 |
| General physical health deteriorationGeneral disorders | 3/87 | 3/86 | 1/41 | 1/20 |
| FatigueGeneral disorders | 0/87 | 2/86 | 1/41 | 1/20 |
| GastroenteritisInfections and infestations | 0/87 | 0/86 | 0/41 | 1/20 |
| Blood glucose increasedInvestigations | 0/87 | 0/86 | 0/41 | 1/20 |
| Transaminases increasedInvestigations | 0/87 | 0/86 | 0/41 | 1/20 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/87 | 0/86 | 0/41 | 1/20 |
| Glucose tolerance impairedMetabolism and nutrition disorders | 0/87 | 0/86 | 0/41 | 1/20 |
| SepsisInfections and infestations | 1/87 | 3/86 | 0/41 | 0/20 |
| Event | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 29/87 | 53/86 | 30/41 | 16/20 |
| VomitingGastrointestinal disorders | 20/87 | 24/86 | 31/41 | 15/20 |
| DiarrhoeaGastrointestinal disorders | 31/87 | 48/86 | 15/41 | 13/20 |
| AnaemiaBlood and lymphatic system disorders | 32/87 | 48/86 | 5/41 | 6/20 |
| AstheniaGeneral disorders | 7/87 | 26/86 | 9/41 | 10/20 |
| Decreased appetiteMetabolism and nutrition disorders | 16/87 | 33/86 | 20/41 | 8/20 |
| FatigueGeneral disorders | 39/87 | 40/86 | 18/41 | 7/20 |
| HyperglycaemiaMetabolism and nutrition disorders | 8/87 | 17/86 | 15/41 | 5/20 |
| AlopeciaSkin and subcutaneous tissue disorders | 31/87 | 27/86 | 1/41 | 0/20 |
| ConstipationGastrointestinal disorders | 25/87 | 20/86 | 14/41 | 5/20 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 63.7 ± 7.14 | 64.4 ± 7.63 | 64.0 ± 6.99 | 62.0 ± 10.20 | 63.9 ± 7.57 |
| Sex: Female, Male(Participants) | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg | Total |
|---|---|---|---|---|---|
| Female | 90 | 90 | 41 | 20 | 241 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 3 | 4 | 15 |
| Not Hispanic or Latino | 84 | 80 | 37 | 15 | 216 |
| Unknown or Not Reported | 3 | 5 | 1 | 1 | 10 |
| Race/Ethnicity, Customized(Participants) | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg | Total |
|---|---|---|---|---|---|
| White | 77 | 78 | 37 | 18 | 210 |
| Black or African American | 3 | 4 | 0 | 1 | 8 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 | 0 | 2 |
| Asian | 6 | 3 | 1 | 1 | 11 |
| Other | 0 | 2 | 2 | 0 | 4 |
| Not Reported | 3 | 3 | 0 | 0 | 6 |
| Region of Enrollment(Participants) | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg | Total |
|---|---|---|---|---|---|
| Australia | 5 | 6 | 3 | 2 | 16 |
| Belgium | 5 | 10 | 2 | 3 | 20 |
| Germany | 6 | 4 | 1 | 0 | 11 |
| Italy | 14 | 22 | 9 | 4 | 49 |
| Netherlands | 2 | 3 | 0 | 0 | 5 |
| Norway | 3 | 1 | 1 | 0 | 5 |
| Spain | 10 | 7 | 5 | 6 | 28 |
| United Kingdom | 9 | 4 | 6 | 2 | 21 |
| Canada | 15 | 10 | 2 | 0 | 27 |
| United States | 21 | 23 | 12 | 3 | 59 |
| Height(cm) | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 160.60 ± 6.335 | 160.23 ± 5.798 | 159.01 ± 6.471 | 162.67 ± 5.854 | 160.36 ± 6.16 |
| Weight(kg) | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 73.29 ± 18.783 | 72.13 ± 18.433 | 75.35 ± 17.969 | 71.81 ± 18.613 | 73.11 ± 18.418 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Apr 2016 to primary completion in Jul 2019, 39 months.
Results were first posted in Jun 2020, 11 months after primary completion.
Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 115. This study's 39 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paclitaxel · Sapanisertib · Serabelisib
Millennium Pharmaceuticals, Inc. →